SCHEMBL4867129

SCHEMBL4867129

COCOc1ccc(C(C)C)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 3/20 0.48
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PPARG P37231 1/20 0.44
PPARD Q03181 1/20 0.44
PPARA Q07869 1/20 0.44
HDAC4 P56524 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
ACHE P22303 2/20 0.41
BCHE P06276 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 2/20 0.39
POLB P06746 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11951566 0.84 FDPS (0.57) FDPSCYP1A2CYP2C9CYP2C19KMT2A
SCHEMBL682781 0.84 GAA (0.56) FDPSKMT2APPARGPPARDPPARA
SCHEMBL15004032 0.83 PPARG (0.54) FDPSCYP1A2CYP2C9CYP2C19KMT2A
SCHEMBL84033 0.82 PPARG (0.53) CYP1A2CYP2C9CYP2C19KMT2ANPSR1
SCHEMBL14200357 0.82 ACHE (0.55) L3MBTL1ACHEBCHESMN1; SMN2ALDH1A1
SCHEMBL11951573 0.82 SMN1; SMN2 (0.54) FDPSKMT2APPARGPPARDPPARA
SCHEMBL12062743 0.82 LMNA (0.41) L3MBTL1ACHEBCHESMN1; SMN2ALDH1A1
SCHEMBL27534706 0.81 FDPS (0.51) FDPSCYP1A2CYP2C9CYP2C19KMT2A
SCHEMBL14293948 0.81 MRGPRX4 (0.38) HDAC4HDAC8ACHEBCHESMN1; SMN2
SCHEMBL2129879 0.81 HDAC4 (0.34) CYP1A2CYP2C9CYP2C19KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-A2 COMT INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-09-06 EP disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition F. HOFFMANN-LA ROCHE AG (CH) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition COMT, MAOB, TPH1 FDPS 1286/4885CYP1A2 20/4885CYP2C9 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.